Related Experiment Videos

Prediction of left ventricular dysfunction progression in patients with a first ST-elevation myocardial

Roksolana Derzhko1, Rafal Plaksej, Monika Przewlocka-Kosmala

  • 1Department of Cardiology, Medical University, Wroclaw, Pasteura, Poland.

Coronary Artery Disease
|September 11, 2009
PubMed

Insights

Predicting post-myocardial infarction left ventricular (LV) dysfunction is crucial. C-reactive protein (CRP) and cystatin C (CystC) aid in predicting LV dysfunction progression and adverse cardiac events after ST-elevation myocardial infarction (STEMI).

Area of Science:

  • Cardiology
  • Biomarker Research
  • Myocardial Infarction Management

Background:

  • Left ventricular (LV) dysfunction significantly impacts outcomes following myocardial infarction (MI).
  • Accurate prediction of post-MI LV dysfunction progression is essential for patient management.
  • The role of cystatin C (CystC) in predicting post-MI complications requires further investigation.

Purpose of the Study:

  • To identify factors predicting the progression of post-infarct LV dysfunction.
  • To evaluate the utility of cystatin C (CystC) in conjunction with other biomarkers for risk stratification.
  • To assess the predictive value of biomarkers for adverse cardiac events in ST-elevation myocardial infarction (STEMI) patients.

Main Methods:

  • A cohort of 150 patients with first ST-elevation myocardial infarction (STEMI) was studied over 6 months.
  • Measurements included NT-proBNP, C-reactive protein (CRP), CystC, and troponin I.
  • Echocardiography was performed at discharge and follow-up; multivariable logistic regression and ROC analyses were employed.

Main Results:

  • LV ejection fraction decrease was independently predicted by CRP, multivessel disease, and left anterior descending artery involvement.
  • Elevated LV filling pressure (E/E' > 15) was associated with CystC, diabetes, and multivessel disease.
  • CRP, NT-proBNP, and CystC independently predicted clinical outcomes; CRP and CystC showed value in discriminating specific echocardiographic changes.

Conclusions:

  • Combining multiple biomarkers enhances the prediction of LV dysfunction progression and adverse events in STEMI patients.
  • Cystatin C (CystC) shows particular promise in improving the evaluation of echocardiographic features indicative of elevated LV filling pressure.
  • Multimarker strategies, including CystC, can refine risk stratification and guide management in post-MI patients.
Abstract

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...